secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-105953
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway
------------------------------------------------------------------------

- Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.
- Net loss $7.5M (Q3 2025) vs $4.2M (Q3 2024); increase driven by $2.0M NXP900 milestone expense.
- R&D expenses $5.8M (Q3 2025) vs $2.8M (Q3 2024), reflecting clinical progress.
- NXP900 Phase 1b single-agent portion initiated; combination arm expected by year-end 2025.
- Phase 1a dose escalation and drug-drug interaction study completed with pharmacodynamic responses at clinically relevant doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925105953/0001104659-25-105953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925105953/tm2530070d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer